PD1

New York, USA, July 26, 2023 (GLOBE NEWSWIRE) -- Anti-CD279 (PD-1) Antibody Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 35+ Companies and Therapies | DelveInsight…

At the American Society of Clinical Oncology (ASCO) annual meeting, researchers reported on a…

Updated findings of KEYNOTE-826, presented at the American Society of Clinical Oncology…

New York, USA, June 20, 2023 (GLOBE NEWSWIRE) -- PD-1 Non-Small Cell Lung Cancer Clinical Trials Pipeline Analysis: 20+ Companies are Working to Improve the Treatment Space | DelveInsight…

An oncolytic virus therapy of cretostimogene grenadenorepvec (CG0070) combined with…

Patients with advanced melanoma had a higher response rate with immunotherapy when they had…

ORLANDO -- Exceedingly high response rates were seen with pembrolizumab (Keytruda) in patients with unresectable metastatic…

The second time proved to be the charm for the PD-1 inhibitor retifanlimab (Zynyz), as the FDA approved the drug for Merkel…

Use of a PD-1/TIGIT inhibitor combination in patients with metastatic non-small cell lung…

紐約水牛城, Dec. 21, 2022 (GLOBE NEWSWIRE) --  Athenex, Inc., (NASDAQ: ATNX)，一家致力於癌症及相關疾病新療法的發現、開發和商業化的全球性生物製藥公司今日宣布，其在 Quantum Leap Healthcare Collaborative 的合作者報告稱公司的口服紫杉醇聯合 encequidar 與…